PETACH TIKVA, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX100 will be highlighted in a podium presentation at the European Society for Coloproctology (ESCP) Scientific Conference to be held on September 21-23, 2022, in Dublin, Ireland.
European Society for Coloproctology Scientific Conference:
||D-PLEX100, a novel doxycycline formulation that provides high, local concentrations of antibiotic activity for 30 days to reduce surgical site infections
||Anthony J. Senagore, M.D., Senior Medical Director, PolyPid
||Wednesday, September 21, 2022, part of the Modern Colorectal Surgeon session